New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials

NCT ID NCT07524348

Recruiting now Disease control Sponsor: Samsung Bioepis Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Apr 14, 2026 · Last updated Jun 16, 2026 · Updated 10 times

Summary

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the drug can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Scottsdale, Arizona, 85258, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
RECRUITING

Adelaide, Australia
Research Site
RECRUITING

Barcelona, Spain

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS